Skip to main content
UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
19.91
-0.55 (-2.69%)
At close: Mar 9, 2026, 4:00 PM EDT
19.80
-0.11 (-0.55%)
After-hours: Mar 9, 2026, 5:11 PM EDT

UroGen Pharma Revenue

In the year 2025, UroGen Pharma had annual revenue of $109.79M with 21.45% growth. UroGen Pharma had revenue of $37.84M in the quarter ending December 31, 2025, with 54.03% growth.

Revenue (ttm)
$109.79M
Revenue Growth
+21.45%
P/S Ratio
8.83
Revenue / Employee
$382,537
Employees
287
Market Cap
969.26M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2025109.79M19.39M21.45%
Dec 31, 202490.40M7.69M9.29%
Dec 31, 202382.71M18.36M28.52%
Dec 31, 202264.36M16.32M33.96%
Dec 31, 202148.04M36.24M307.17%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Pharming Group 362.27M
Xeris Biopharma Holdings 291.85M
Geron 183.88M
AbCellera Biologics 75.13M
Aktis Oncology 5.56M
Inhibrx Biosciences 1.40M
Compass Therapeutics 850.00K
Revenue Rankings

URGN News

More News